ProMetic to Report its Fourth Quarter and Year End 2012 Financial Results and Hold Conference Call/W

ProMetic to Report its Fourth Quarter and Year End 2012 Financial Results and Hold Conference Call/Webcast

ID: 240955

(firmenpresse) - LAVAL, QUEBEC -- (Marketwire) -- 03/19/13 -- ProMetic Life Sciences Inc. (TSX: PLI) ("ProMetic" or the "Corporation") today announced that it will report its financial results for the fourth quarter and fiscal year ended December 31, 2012 on Tuesday, March 26, 201 3 after market trading hours.

ProMetic will host a conference call at 11:00am (EDT) on Wednesday, March 27, 2013. The telephone numbers to access the conference call are (416) 981-9000 (International) and 1-800-755-1805 (North America Toll-Free). A live audio webcast of the conference call will be available via

An audio replay of the call will be available for a period of seven days as of Wednesday March 27, 2013, at 1:30pm (EDT). The numbers to access the audio replay are (416) 626-4100 (international) and 1 (800) 558-5253 (North America Toll Free) using access code: 21652529.

About ProMetic Life Sciences Inc.

ProMetic Life Sciences Inc. ("ProMetic") () is a biopharmaceutical company specialized in the research, development, manufacture and marketing of a variety of commercial applications derived from its proprietary Mimetic Ligand™ technology. This technology is used in large-scale purification of biologics and the elimination of pathogens. ProMetic is also active in therapeutic drug development with the mission to bring to market effective, innovative, lower cost, less toxic products for the treatment of hematology and cancer. Its drug discovery platform is focused on replacing complex, expensive proteins with synthetic "drug-like" protein mimetics. Headquartered in Laval (Canada), ProMetic has R&D facilities in the U.K., the U.S. and Canada, manufacturing facilities in the U.K. and business development activities in the US, Europe, Asia.



Contacts:
Pierre Laurin
President and CEO
ProMetic Life Sciences Inc.

450.781.0115

Frederic Dumais
Director, Communications and
Investor Relations
ProMetic Life Sciences





450-781-0115

Weitere Infos zu dieser Pressemeldung:

Themen in dieser Pressemitteilung:


Unternehmensinformation / Kurzprofil:
drucken  als PDF  an Freund senden  Soricimed's Peptides Used to Detect Ovarian and Prostate Cancer 3.8 Million Euro Grant to Support CVAC(TM) Development; Prima Moving Forward With Pilot Trials of CVAC in Additional Cancer Indications
Bereitgestellt von Benutzer: MARKETWIRE
Datum: 19.03.2013 - 16:03 Uhr
Sprache: Deutsch
News-ID 240955
Anzahl Zeichen: 0

contact information:
Town:

LAVAL, QUEBEC



Kategorie:

Biotech



Diese Pressemitteilung wurde bisher 198 mal aufgerufen.


Die Pressemitteilung mit dem Titel:
"ProMetic to Report its Fourth Quarter and Year End 2012 Financial Results and Hold Conference Call/Webcast"
steht unter der journalistisch-redaktionellen Verantwortung von

ProMetic Life Sciences Inc. (Nachricht senden)

Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).

ProMetic's IVIG IND Cleared by FDA ...

LAVAL, QUEBEC -- (Marketwired) -- 10/26/15 -- ProMetic Life Sciences Inc. (TSX: PLI)(OTCQX: PFSCF) ("ProMetic" or the "Corporation") announced today that the US Food and Drug Administration ("FDA") has completed its re ...

Alle Meldungen von ProMetic Life Sciences Inc.



 

Werbung



Facebook

Sponsoren

foodir.org The food directory für Deutschland
Informationen für Feinsnacker finden Sie hier.

Firmenverzeichniss

Firmen die firmenpresse für ihre Pressearbeit erfolgreich nutzen
1 2 3 4 5 6 7 8 9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z